Annovis Bio registers long-term safety study of buntanetap in Alzheimer's disease
A new open-label trial will track safety outcomes for participants who previously took buntanetap in Alzheimer's disease studies.
Annovis Bio's only new item this week is a registry listing for a follow-on safety trial of its Alzheimer's drug candidate.
- **Buntanetap (posiphen), Phase 2/3, Alzheimer's Disease**: Registered, not yet recruiting. This is a 24-month open-label safety study1 in which participants must have taken part in a prior Alzheimer's clinical trial with buntanetap1. The study plans to enroll 400 participants1 and is sponsored by Annovis Bio Inc.1, with an estimated start date of September 21, 2026 and primary completion date of February 21, 2030.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.